末梢神経障害市場レポート：2030年までの動向、予測、競合分析

末梢神経障害の動向と予測

世界の末梢神経障害市場は、2024年から2030年にかけてCAGR 7.0％で成長すると予測されます。この市場の主な促進要因は、老年人口と肥満人口の急増、糖尿病の増加です。世界の末梢神経障害市場の将来は、病院・診療所および外来センター市場における機会によって有望視されています。

末梢神経障害市場の洞察

Lucintelの予測では、薬物療法はより効果的で使いやすいため、予測期間中は薬物療法がより大きなセグメントであり続けると思われます。

この市場の中では、病院や診療所の方が、さまざまな治療法が利用可能であり、これらの施設に専門家がいるため、より大きなセグメントであり続けると思われます。

北米は糖尿病患者の有病率が高く、ヘルスケアインフラが整備されているため、予測期間中も最大の地域です。

よくある質問

Q1.市場の成長予測は？

A1.世界の末梢神経障害市場は、2024年から2030年にかけてCAGR 7.0％で成長すると予測されています。

Q2.市場の成長に影響を与える主な促進要因は？

A2.この市場の主な促進要因は、老人・肥満人口の急増と糖尿病の増加です。

Q3.市場の主要セグメントは？

A3.末梢神経障害市場の将来性は、病院・診療所および外来センター市場での機会により有望視されます。

Q4.市場の主要企業は？

A4.末梢神経障害の主要企業は以下の通りです。

• Abbott
• Bristol Myers Squibb
• Novartis
• Eli Lilly
• Pfizer

Q5.今後、最大となる市場セグメントは？

A5.Lucintelは、薬物療法はより効果的で使いやすいため、予測期間中、より大きなセグメントであり続けると予測しています。

Q6.市場において、今後5年間に最大になると予想される地域は？

A6.北米は糖尿病患者の有病率が高く、ヘルスケアインフラが整備されているため、予測期間中も最大地域であり続ける。

Q7.レポートのカスタマイズは可能？

A7.はい、Lucintelは追加費用なしで10%のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界の末梢神経障害市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界の末梢神経障害市場動向（2018-2023）と予測（2024-2030）
• タイプ別の世界の末梢神経障害市場
  • 糖尿病性末梢神経障害
  • 化学療法誘発性末梢神経障害
  • 特発性末梢神経障害
  • HIV/AIDS関連の末梢神経障害
• 治療別の世界の末梢神経障害市場
  • 薬物療法
  • 非薬物療法
  • その他
• 最終用途別の世界の末梢神経障害市場
  • 病院と診療所
  • 外来センター
  • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

• 地域別の世界の末梢神経障害市場
• 北米の末梢神経障害市場
• 欧州の末梢神経障害市場
• アジア太平洋の末梢神経障害市場
• その他地域の末梢神経障害市場

第5章 競合の分析

• 製品ポートフォリオ分析
• 運用上の統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

• 成長機会分析
  • タイプ別の世界の末梢神経障害市場の成長機会
  • 治療別の世界の末梢神経障害市場の成長機会
  • 最終用途別の世界の末梢神経障害市場の成長機会
  • 地域別の世界の末梢神経障害市場の成長機会
• 世界の末梢神経障害市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界の末梢神経障害市場の能力拡大
  • 世界の末梢神経障害市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 有力企業の企業プロファイル

• Abbott
• Bristol Myers Squibb
• Novartis
• Eli Lilly
• Pfizer

Peripheral Neuropathy Trends and Forecast

The future of the global peripheral neuropathy market looks promising with opportunities in the hospital and clinic and ambulatory center markets. The global peripheral neuropathy market is expected to grow with a CAGR of 7.0% from 2024 to 2030. The major drivers for this market are surge in geriatric and obese population and increasing occurence of diabetes.

A more than 150-page report is developed to help in your business decisions.

Peripheral Neuropathy by Segment

The study includes a forecast for the global peripheral neuropathy by type, treatment, end use, and region.

Peripheral Neuropathy Market by Type [Shipment Analysis by Value from 2018 to 2030]:

• Diabetic Peripheral Neuropathy
• Chemotherapy-Induced Peripheral Neuropathy
• Idiopathic Peripheral Neuropathy
• HIV/AIDS Associated Peripheral Neuropathy

Peripheral Neuropathy Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

• Pharmacological Therapies
• Non-Pharmacological Therapies
• Others

Peripheral Neuropathy Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals and Clinics
• Ambulatory Centers
• Others

Peripheral Neuropathy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Peripheral Neuropathy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies peripheral neuropathy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the peripheral neuropathy companies profiled in this report include-

• Abbott
• Bristol Myers Squibb
• Novartis
• Eli Lilly
• Pfizer

Peripheral Neuropathy Market Insights

Lucintel forecasts that pharmacological therapy will remain the larger segment over the forecast period as it is more effective and easy to use.

Within this market, hospital and clinic will remain the larger segment due to availability of different treatment methods along with presence of expertise in these facilities.

North America will remain the largest region over the forecast period due to high prevalence of diabetes patients and presence of healthcare infrastructure in the region.

Features of the Global Peripheral Neuropathy Market

Market Size Estimates: Peripheral neuropathy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Peripheral neuropathy market size by type, treatment, end use, and region in terms of value ($B).

Regional Analysis: Peripheral neuropathy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, treatment, end uses, and regions for the peripheral neuropathy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the peripheral neuropathy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for peripheral neuropathy market?

Answer: The global peripheral neuropathy market is expected to grow with a CAGR of 7.0% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the peripheral neuropathy market?

Answer: The major drivers for this market are surge in geriatric and obese population and increasing occurence of diabetes.

Q3. What are the major segments for peripheral neuropathy market?

Answer: The future of the peripheral neuropathy market looks promising with opportunities in the hospital and clinic and ambulatory center markets.

Q4. Who are the key peripheral neuropathy market companies?

Answer: Some of the key peripheral neuropathy companies are as follows.

• Abbott
• Bristol Myers Squibb
• Novartis
• Eli Lilly
• Pfizer

Q5. Which peripheral neuropathy market segment will be the largest in future?

Answer: Lucintel forecasts that pharmacological therapy will remain the larger segment over the forecast period as it is more effective and easy to use.

Q6. In peripheral neuropathy market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to high prevalence of diabetes patients and presence of healthcare infrastructure in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the peripheral neuropathy market by type (diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, idiopathic peripheral neuropathy, and HIV/AIDS associated peripheral neuropathy), treatment (pharmacological therapies, non-pharmacological therapies, and others), end use (hospitals and clinics, ambulatory centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Peripheral Neuropathy Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Peripheral Neuropathy Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Peripheral Neuropathy Market by Type
  • 3.3.1: Diabetic Peripheral Neuropathy
  • 3.3.2: Chemotherapy-induced Peripheral Neuropathy
  • 3.3.3: Idiopathic Peripheral Neuropathy
  • 3.3.4: HIV/AIDS Associated Peripheral Neuropathy
• 3.4: Global Peripheral Neuropathy Market by Treatment
  • 3.4.1: Pharmacological Therapies
  • 3.4.2: Non-Pharmacological Therapies
  • 3.4.3: Others
• 3.5: Global Peripheral Neuropathy Market by End Use
  • 3.5.1: Hospitals and Clinics
  • 3.5.2: Ambulatory Centers
  • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Peripheral Neuropathy Market by Region
• 4.2: North American Peripheral Neuropathy Market
  • 4.2.1: North American Peripheral Neuropathy Market by Treatment: Pharmacological Therapies, Non-Pharmacological Therapies, and Others
  • 4.2.2: North American Peripheral Neuropathy Market by End Use: Hospitals and Clinics, Ambulatory Centers, and Others
• 4.3: European Peripheral Neuropathy Market
  • 4.3.1: European Peripheral Neuropathy Market by Treatment: Pharmacological Therapies, Non-Pharmacological Therapies, and Others
  • 4.3.2: European Peripheral Neuropathy Market by End Use: Hospitals and Clinics, Ambulatory Centers, and Others
• 4.4: APAC Peripheral Neuropathy Market
  • 4.4.1: APAC Peripheral Neuropathy Market by Treatment: Pharmacological Therapies, Non-Pharmacological Therapies, and Others
  • 4.4.2: APAC Peripheral Neuropathy Market by End Use: Hospitals and Clinics, Ambulatory Centers, and Others
• 4.5: ROW Peripheral Neuropathy Market
  • 4.5.1: ROW Peripheral Neuropathy Market by Treatment: Pharmacological Therapies, Non-Pharmacological Therapies, and Others
  • 4.5.2: ROW Peripheral Neuropathy Market by End Use: Hospitals and Clinics, Ambulatory Centers, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Peripheral Neuropathy Market by Type
  • 6.1.2: Growth Opportunities for the Global Peripheral Neuropathy Market by Treatment
  • 6.1.3: Growth Opportunities for the Global Peripheral Neuropathy Market by End Use
  • 6.1.4: Growth Opportunities for the Global Peripheral Neuropathy Market by Region
• 6.2: Emerging Trends in the Global Peripheral Neuropathy Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Peripheral Neuropathy Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Peripheral Neuropathy Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Abbott
• 7.2: Bristol Myers Squibb
• 7.3: Novartis
• 7.4: Eli Lilly
• 7.5: Pfizer